- Home
- CRGX vs ORIC Comparison
CRGX vs ORIC Comparison
Compare CRGX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ORIC
- Stock Information
- Founded
- CRGX 2021
- ORIC 2014
- Country
- CRGX United States
- ORIC United States
- Employees
- CRGX N/A
- ORIC N/A
- Industry
- CRGX
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- ORIC Health Care
- Exchange
- CRGX Nasdaq
- ORIC Nasdaq
- Market Cap
- CRGX 628.6M
- ORIC 735.3M
- IPO Year
- CRGX 2023
- ORIC 2020
- Fundamental
- Price
- CRGX $3.70
- ORIC $10.84
- Analyst Decision
- CRGX Hold
- ORIC Strong Buy
- Analyst Count
- CRGX 7
- ORIC 9
- Target Price
- CRGX $4.67
- ORIC $18.75
- AVG Volume (30 Days)
- CRGX 1.9M
- ORIC 825.1K
- Earning Date
- CRGX 03-20-2025
- ORIC 03-10-2025
- Dividend Yield
- CRGX N/A
- ORIC N/A
- EPS Growth
- CRGX N/A
- ORIC N/A
- EPS
- CRGX N/A
- ORIC N/A
- Revenue
- CRGX N/A
- ORIC N/A
- Revenue This Year
- CRGX N/A
- ORIC N/A
- Revenue Next Year
- CRGX N/A
- ORIC N/A
- P/E Ratio
- CRGX N/A
- ORIC N/A
- Revenue Growth
- CRGX N/A
- ORIC N/A
- 52 Week Low
- CRGX $3.00
- ORIC $6.33
- 52 Week High
- CRGX $33.92
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- CRGX 20.88
- ORIC 52.90
- Support Level
- CRGX $3.00
- ORIC $9.92
- Resistance Level
- CRGX $3.88
- ORIC $12.00
- Average True Range (ATR)
- CRGX 0.92
- ORIC 0.90
- MACD
- CRGX -1.00
- ORIC 0.04
- Stochastic Oscillator
- CRGX 5.99
- ORIC 41.82
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.